future of parp inhibitors for urothelial carcinoma
Published 2 years ago • 19 plays • Length 2:20Download video MP4
Download video MP3
Similar videos
-
0:51
future of urothelial carcinoma research
-
3:44
the future role of parp inhibition in ovarian cancer
-
4:00
upcoming therapies in the metastatic urothelial carcinoma space
-
2:05
dr. coleman on the future of parp inhibitors in ovarian cancer
-
3:34
future of parp inhibitors in mcrpc
-
2:05
the evolving treatment landscape of advanced and metastatic urothelial carcinoma
-
1:02
where can parp inhibitors be used
-
1:09
futibatinib plus pembrolizumab for the treatment of advanced or metastatic urothelial carcinoma
-
42:41
round-table discussion on parp inhibitor
-
6:14
standard of care and progress with parp inhibitors for ovarian cancer
-
1:49
blc2001: erdafitinib for the treatment of metastatic urothelial carcinoma
-
1:25
parp inhibitors for ovarian cancer - room for improvement with hrd testing
-
4:49
parp combinations: the future
-
2:12
looking towards the future: what is in store for the treatment of bladder cancer?
-
1:28
erdafitinib for bladder cancer: more to come following fda approval
-
1:02
maintenance therapy in urothelial carcinoma
-
1:39
challenges in the field of parpi treatment for mcrpc
-
2:31
key immunotherapy combinations for urothelial cancer
-
6:44
asco 2021: developments in urothelial cancer treatment